Another great American Society of Clinical Oncology (ASCO) meeting in the books! What an incredible feeling to get to be back in person after two years off. This year did not disappoint with great presentations across the board.
We’re still buzzing about DESTINY-Breast04! The standing ovation and roaring applause were truly something spectacular. The trial results were published in The New England Journal of Medicine (NEMJ) and shared during the plenary session by Dr. Shanu Mondi. The results demonstrated significantly longer PFS (9.9 vs 5.1 mo, HR0.50) and OS (23.4 vs 16.8 mo, HR0.64) for T-DXd vs standard chemo in pretreated HER2-low MBC, thereby establishing T-DXd as the new standard of care for this patient population.
The LUPER trial is a clinical and pharmacokinetic study of lurbinectedin in combination with pembrolizumab for patients with relapsed small cell lung cancer. 13 patients from three hospitals in were enrolled in the study. In terms of patient characteristics, there was a median age of 66 years, 6.2% were female, 61.5% had ECOG PS of 1, 38.5% had platinum-free interval < 90 days, 30.8% had LDH > upper normal limit, and 15.4% had brain metastases. In dose level 1 (2.4mg/m2) there was one dose limiting toxicity (grade 3 asthenia) and one grade 4 neutropenia that lasted greater than 3 days. No dose limiting toxicities were experience in dose level 2 (3.2mg/m2). At data cutoff there were 5 patients still on treatment. One patient had to discontinue treatment due to COVID-19 and two patients discontinued due to immune-related adverse events. Responses were seen in both dose levels with an overall response rate of 30.8%. Click here to download the full poster.
“The LUPER trial presents a unique opportunity for patients with relapsed small-cell lung cancer as it combines immunotherapy with chemotherapy for a patient population that has not had therapeutic advances in the last 20 years.” Antonio Calles, MD, from Hospital General Universitario Gregorio Marañón
The ATRACTIB trial is evaluating the efficacy and safety of first line atezolizumab combined with paclitaxel and bevacizumab in patients with advanced or metastatic triple-negative breast cancer. At this meeting were shared interim safety analysis. There were 34 patients enrolled at 13 sites in Spain and Germany. In terms of patient characteristics, the median age was 57.5 years, 23 pts had received prior CT for early disease, and 19 had visceral disease. At data cutoff 71.4% of patients were still receiving the drug regimen, with three discontinuing due to adverse events. Five patients required a dose delay due to adverse events. Fatigue (47.1%; 8.8% G≥3), diarrhea (38.2%; 0% G≥3), and neurotoxicity (35.3%; 8.8% G≥3) were the most common adverse event of any grade, with anemia (20.6%; 0% G≥3) and neutropenia (17.6%; 8.8% G≥3) as the most frequent hematological adverse events. Hypertension (17.6%; 5.9% G≥3) and pulmonary embolism (2.9%; 0% G≥3) were experienced as a result of bevacizumab treatment. There were no treatment-related deaths. The full poster can be downloaded here.
“The ATRACTIB clinical trial is a promising opportunity for patients with metastatic triple-negative breast cancer that combines three of the best drugs available today for first-line treatment in a unique and well-tolerated regimen of theraoy with paclitaxel + bevacizumab + atezolizumab regardless of PD-L1 status. This combination could represent, in the future, a good option for this population who still have a very poor prognosis." María Gion, MD from Hospital Universitario Ramón y Cajal (Madrid) & IOB Hospital Ruber Internacional (Madrid)
With all the fantastic presentations and the great networking opportunities we had a wonderful time at ASCO and want to thank the organizers for putting together the meeting. We look forward to ASCO 2023!
Contact us if you want to learn more about these trials or wish to collaborate!
For a great summary of presentations from ASCO, Bertrand Delsuc compiled tweets from ASCO (Part 1, Part 2, Part 3, Part 4), and our tweets are featured in them! And of course, browsing through our own twitter page will give you many of the great highlights from the meeting.